Sugi Predict

Sugi Predict / Targets / NPY2R

NPY2R

Neuropeptide Y receptor type 2 · P49146 · NPY2R on Sugi Atlas →

70,586 patent compounds predicted against NPY2R, 42,354 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL353733 SCHEMBL353733 1.00 20/20
SCHEMBL353765 SCHEMBL353765 1.00 20/20
SCHEMBL354490 SCHEMBL354490 1.00 20/20
SCHEMBL354833 SCHEMBL354833 1.00 20/20
SCHEMBL355076 SCHEMBL355076 1.00 20/20
SCHEMBL355438 SCHEMBL355438 1.00 20/20
SCHEMBL355495 SCHEMBL355495 1.00 20/20
SCHEMBL355526 SCHEMBL355526 1.00 20/20
SCHEMBL355546 SCHEMBL355546 1.00 20/20
SCHEMBL355556 SCHEMBL355556 1.00 20/20
SCHEMBL355793 SCHEMBL355793 1.00 20/20
SCHEMBL355802 SCHEMBL355802 1.00 20/20
SCHEMBL355838 SCHEMBL355838 1.00 20/20
SCHEMBL356338 SCHEMBL356338 1.00 20/20
SCHEMBL356439 SCHEMBL356439 1.00 20/20
SCHEMBL356671 SCHEMBL356671 1.00 20/20
SCHEMBL356708 SCHEMBL356708 1.00 20/20
SCHEMBL356902 SCHEMBL356902 1.00 20/20
SCHEMBL356489 SCHEMBL356489 0.94 20/20
SCHEMBL355777 SCHEMBL355777 0.92 20/20

Clinical trials — most relevant to NPY2R by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Medication, Weight Gain and GI Hormones PHASE4COMPLETED
Saxenda: Underlying Mechanisms and Clinical Outcomes PHASE4ACTIVE_NOT_RECRUITING
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion PHASE4RECRUITING
Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep PHASE3COMPLETED
Brain Activation and Satiety in Children 2 PHASE3ACTIVE_NOT_RECRUITING
Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA) PHASE3COMPLETED
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment PHASE1/PHASE2RECRUITING
Effects of Exenatide on Hypothalamic Obesity PHASE1/PHASE2COMPLETED
Repurposing Semaglutide for the Treatment of Cocaine Use Disorder PHASE2RECRUITING
Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder PHASE1/PHASE2UNKNOWN
Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers PHASE2COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
Neuropeptide Y and Sympathovagal Balance EARLY_PHASE1COMPLETED
Degradation of the Anorexic Hormone Peptide YY EARLY_PHASE1COMPLETED
Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma nanCOMPLETED
In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors nanCOMPLETED
Auricular Vagus Stimulation in Obesity nanACTIVE_NOT_RECRUITING
Functional MRI Evaluation of Brain Response to Visual Food Stimulation in Morbidly Obese Patients Before and After Bariatric Surgery nanCOMPLETED
The Progress of Diabetes After Supaglutide Treatment in Type 2 Diabetes Patients nanRECRUITING
Acylated Ghrelin Response to Acute Exercise in Obesity nanCOMPLETED
Brain-Derived Neurotrophic Factor in Obesity and Brain Function nanCOMPLETED
GLP-1 Receptor Expression in CHI nanUNKNOWN
The Effect of Weekly Semaglutide Treatment on Energy Expenditure nanCOMPLETED
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention nanNOT_YET_RECRUITING
Colonic Propionate, Appetite, and Weight Loss nanCOMPLETED
The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes nanCOMPLETED
Macronutrient Regulation of Ghrelin and Peptide YY nanCOMPLETED
RCT to Describe the Effects of Colon Delivered Acetate, Propionate and Butyrate on Satiety and Glucose Homeostasis nanCOMPLETED
Investigating Optimal Propionate Delivery to the Colon Using Stable Isotope Labeling nanCOMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a NPY2R binder may also engage these)

ProteinNameSimilarity
P97295 — 1.000 P97295 →
Q5IS62 — 1.000 Q5IS62 →
Q9GK74 — 1.000 Q9GK74 →
Q9Z2D5 — 1.000 Q9Z2D5 →
Q9DDN6 — 1.000 Q9DDN6 →
P79113 — 1.000 P79113 →
O02836 — 1.000 O02836 →
O62809 — 0.985 O62809 →
O02835 — 0.983 O02835 →
Q9EQD2 — 0.983 Q9EQD2 →
Q924H0 — 0.981 Q924H0 →
P34992 — 0.981 P34992 →
Q04573 — 0.981 Q04573 →
Q8K458 — 0.981 Q8K458 →
PROKR2 Prokineticin receptor 2 0.980 landscape →
Q8SPN1 — 0.980 Q8SPN1 →
P47751 — 0.979 P47751 →
Q1RMU8 — 0.978 Q1RMU8 →
Q9TUP7 — 0.978 Q9TUP7 →
O02813 — 0.978 O02813 →
NPY1R Neuropeptide Y receptor type 1 0.977 landscape →
P21555 — 0.977 P21555 →
P58308 — 0.976 P58308 →
Q8WPA2 — 0.976 Q8WPA2 →
Q8R415 — 0.975 Q8R415 →
Q9JKL1 — 0.975 Q9JKL1 →
HCRTR2 Orexin receptor type 2 0.974 landscape →
Q8SPN2 — 0.974 Q8SPN2 →
Q9WVD0 — 0.974 Q9WVD0 →
Q8R416 — 0.973 Q8R416 →